Colorectal Cancer |
Colon and Rectal Cancer |
Clinical Trial: A Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Following Treatment with Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy
This study is currently recruiting patients.
|
Purpose
The purpose of this study is to determine that ABX-EGF will have clinically meaningful anti-tumor activity in patients with metastatic colorectal cancer who have developed progressive disease or relapsed while on or after prior fluoropyrimidine, irinotecan and oxaliplatin chemotherapy.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Colorectal Cancer Metastases | Drug: ABX-EGF | Phase II |
MedlinePlus related topics: Cancer; Cancer Alternative Therapy; Colorectal Cancer
Study Type: Interventional
Study Design: Treatment
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Pathologic diagnosis of colorectal adenocarcinoma (diagnostic tissue obtained by tissue biopsy)
- Metastatic colorectal carcinoma
- Eastern Cooperative Oncology Group of 0, 1 or 2
- Documented evidence of disease progression during, or following treatment, with fluoropyrimidine, irinotecan and oxaliplatin chemotherapy for metastatic colorectal cancer
- Radiographic documentation of disease progression during or within 6 months following the most recent chemotherapy regimen is required
- Bidimensionally measurable disease
- Tumor expressing EGFr by immunohistochemistry
- At least 2 but no more than 3 prior chemotherapy regimens for metastatic colorectal cancer
- Adequate hematologic, renal and hepatic function
Exclusion Criteria:
- Symptomatic brain metastases requiring treatment
- Patient with a history of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis
- Use of systemic chemotherapy or radiotherapy within 30 days before enrollment
- Prior epidermal growth factor receptor targeting agents
- Prior anti-tumor therapies including prior experimental agents or approved anti-tumor small molecules and biologics of short (less than 1 week) serum half-life within 30 days before enrollment, or prior experimental or approved proteins within 3 months before enrollment
Location and Contact Information
Alabama
Research Site, Montgomery, Alabama, United States; Recruiting
Research Site, Florence, Alabama, United States; Recruiting
Arizona
Research Site, Lake Havasu City, Arizona, United States; Recruiting
California
Research Site, Loma Linda, California, United States; Recruiting
Research Site, Los Angeles, California, United States; Recruiting
Research Site, Redding, California, United States; Recruiting
Research Site, Burbank, California, United States; Recruiting
Colorado
Research Site, Denver, Colorado, United States; Recruiting
Research Site, Aurora, Colorado, United States; Recruiting
Research Site, Colorado Springs, Colorado, United States; Recruiting
Research Site, Littleton, Colorado, United States; Recruiting
Research Site, Boulder, Colorado, United States; Recruiting
Research Site, Thornton, Colorado, United States; Recruiting
Connecticut
Research Site, Norwich, Connecticut, United States; Recruiting
Research Site, Stamford, Connecticut, United States; Recruiting
District of Columbia
Research Site, Washington, District of Columbia, United States; Recruiting
Florida
Research Site, Jacksonville, Florida, United States; Recruiting
Research Site, Miami, Florida, United States; Recruiting
Research Site, Orange Park, Florida, United States; Recruiting
Research Site, Stuart, Florida, United States; Recruiting
Georgia
Research Site, Augusta, Georgia, United States; Recruiting
Research Site, Atlanta, Georgia, United States; Recruiting
Idaho
Research Site, Boise, Idaho, United States; Recruiting
Illinois
Research Site, Harvey, Illinois, United States; Recruiting
Research Site, Skokie, Illinois, United States; Recruiting
Research Site, Libertyville, Illinois, United States; Recruiting
Research Site, Chicago, Illinois, United States; Recruiting
Research Site, Evanston, Illinois, United States; Recruiting
Indiana
Research Site, Indianapolis, Indiana, United States; Recruiting
Research Site, New Albany, Indiana, United States; Recruiting
Kentucky
Research Site, Paducah, Kentucky, United States; Recruiting
Maryland
Research Site, Baltimore, Maryland, United States; Recruiting
Research Site, Towson, Maryland, United States; Recruiting
Michigan
Research Site, Flint, Michigan, United States; Recruiting
Research Site, Grand Rapids, Michigan, United States; Recruiting
Research Site, St. Joseph, Michigan, United States; Recruiting
Missouri
Research Site, Kansas City, Missouri, United States; Recruiting
Montana
Research Site, Billings, Montana, United States; Recruiting
Nebraska
Research Site, Omaha, Nebraska, United States; Recruiting
New Jersey
Research Site, Mt. Holly, New Jersey, United States; Recruiting
Research Site, Howell, New Jersey, United States; Recruiting
Research Site, Cherry Hill, New Jersey, United States; Recruiting
Research Site, Morristown, New Jersey, United States; Recruiting
New Mexico
Research Site, Santa Fe, New Mexico, United States; Recruiting
New York
Research Site, New York, New York, United States; Recruiting
Research Site, Bronx, New York, United States; Recruiting
Research Site, Manhasset, New York, United States; Recruiting
Research Site, Buffalo, New York, United States; Recruiting
Research Site, Fresh Meadows, New York, United States; Recruiting
Research Site, Northport, New York, United States; Recruiting
North Carolina
Research Site, Charlotte, North Carolina, United States; Recruiting
Research Site, Chapel Hill, North Carolina, United States; Recruiting
Ohio
Research Site, Columbus, Ohio, United States; Recruiting
Research Site, Canton, Ohio, United States; Recruiting
Research Site, Cleveland, Ohio, United States; Recruiting
Research Site, Westerville, Ohio, United States; Recruiting
Oklahoma
Research Site, Oklahoma City, Oklahoma, United States; Recruiting
Pennsylvania
Research Site, Philadelphia, Pennsylvania, United States; Recruiting
Research Site, Pittsburgh, Pennsylvania, United States; Recruiting
Rhode Island
Research Site, Cranston, Rhode Island, United States; Recruiting
South Carolina
Research Site, Hilton Head, South Carolina, United States; Recruiting
Research Site, Charleston, South Carolina, United States; Recruiting
Tennessee
Research Site, Nashville, Tennessee, United States; Recruiting
Research Site, Collierville, Tennessee, United States; Recruiting
Research Site, Chatanooga, Tennessee, United States; Recruiting
Research Site, Jackson, Tennessee, United States; Recruiting
Research Site, Knoxville, Tennessee, United States; Recruiting
Research Site, Memphis, Tennessee, United States; Recruiting
Texas
Research Site, Dallas, Texas, United States; Recruiting
Research Site, Houston, Texas, United States; Recruiting
Research Site, Richardson, Texas, United States; Recruiting
Research Site, Amarillo, Texas, United States; Recruiting
Research Site, Austin, Texas, United States; Recruiting
Utah
Research Site, Salt Lake City, Utah, United States; Recruiting
Research Site, Ogden, Utah, United States; Recruiting
Virginia
Research Site, Abingdon, Virginia, United States; Recruiting
Washington
Research Site, Seattle, Washington, United States; Recruiting
Wisconsin
Research Site, Madison, Wisconsin, United States; Recruiting
Research Site, Racine, Wisconsin, United States; Recruiting
Research Site, Milwaukee, Wisconsin, United States; Recruiting
More Information
AmgenTrials clinical trials website
Center Watch Clinical Trials Listing Service
Record last reviewed: December 2004
Last Updated: December 21, 2004
Record first received: May 26, 2004
ClinicalTrials.gov Identifier: NCT00083616
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Not Signed In -


